CC-90005 is a potent, selective and orally active inhibitor of protein kinase C-θ (PKC-θ), with an IC50 of 8 nM. CC-90005 shows selectivity for PKC-θ over PKC-δ (IC50=4440 nM). CC-90005 can inhibit T cell activation by IL-2 expression.

GSK3494245 (DDD01305143) is a potent, orally active, and selective inhibitor of the chymotrypsin-like activity of the parasite proteasome binding in a site sandwiched between the β4 and β5 subunits (IC50=0.16 μM for WT L. donovani proteasomes). GSK3494245 moderately inhibits chymotrypsin-like activity of human proteasome (IC50: purified 26S=13 µM; enriched THP-1 extracts IC50=40µM). GSK3494245 exhibits attractive biological and biosafety properties.

PU-WS13 is a selective Grp94 inhibitor, with an EC50 of 0.22 μM.

LXE408 is a kinetoplastid-selective proteasome inhibitor with IC50 of 40 nM.

GSK789 is a potent, cell-permeable and highly selective inhibitor of the first bromodomains (BD1) with greater than 1000-fold selectivity for the BD1 domains over the BD2s.

RP 70676 is a potent and orally bioavailable inhibitor of ACAT.

CID755673 is a potent and selective cell-active small molecule inhibitor for PKD with an IC50 of 182 nM; exhibits selective PKD1 inhibition when compared with AKT, PLK1, CAK, CAMKIIα, and PKC isoforms.

TTK21 (CBP-p300 activator TTK21) is a small molecule activator of CBP/p300 histone acetyltransferase activity with a maximal effect at a concentration of 275 uM.

A cell-permeable benzochromene that selectively impairs the viability and growth of IGF2-overexpressing hepatocellular carcinoma cells, binds to MFP-2, stimulates the expression of IGFBP-1 and SOCS-3 through activation of STAT6.

A potent, selective, brain penetrant PDE10A inhibitor with Ki of 4 nM.

Glucosylceramide synthase-IN-2 (compound T-690) is a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 15 nM and 190 nM for human GCS and mouse GCS, respectively.

AnCoA4 (AnCoA-4, AnCoA 4) is a potent Orai1 channel inhibitor that inhibits store-operated calcium (SOC) with EC50 of 0.88 uM.

N2-OH-PhIP is a PhIP metabolite.

JP-153 (JP153) is a novel small molecule targets the Src-FAK-Paxillin signaling, inhibits Src-dependent phosphorylation of paxillin (Y118) and downstream activation of Akt (S473) in RECs; potently inhibits VEGF-induced proliferation and migration, inhibits retinal neovascularization in the murine oxygen-induced retinopathy model.

GW274150 is a novel arginine-competitive, NADPH-dependent iNOS inhibitor that has been identified from a series of acetamide amino acids that have a high selectivity for iNOS vs both eNOS (> 260-fold) and nNOS (> 219-fold) and high bioavailability (> 90%) after oral administration.Target: iNOSin vivo: GW274150 demonstrates a narrow neuroprotective therapeutic window against the toxic actions of 6-OHDA. GW274150 administration leads to a dose-dependent decrease in the number of iNOS-positive cells in the SNc of the 6-OHDA-lesioned animals. The iNOS inhibitor GW274150 fails to produce long-term neuroprotection after its withdrawal in the 6-OHDA-lesioned rat. [1]

GSK-J1 is a potent and selective inhibitor of the H3K27 histone demethylases JMJD3 and UTX (IC50 = 60 nM for human JMJD3 in vitro).

LUN09945 is a potent RETV804M kinase inhibitor. LUN09945 was first reported by Rebecca Newton et al (Compound 13, in ACS Med Chem Lett. 2020;11(4):497-505). This product has no formal name at the moment. For the convenience of communication, a temporary code name was therefore proposed according to MedKoo Chemical Nomenclature

8-Azaadenosine is a potent ADAR1 inhibitor and an A-to-I editing inhibitor. 8-Azaadenosine blocks RNA editing and inhibits proliferation, 3D growth, invasion, and migration in thyroid cancer cells.

(R)-V-0219 is an enantiomer of V-0219. V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (R)-V-0219 activates calcium fluxes in HEK cells stably expressing hGLP-1R.

RAY1216 is an orally active SARS-CoV-2 main protease slow-tight inhibitor with a Ki of 8.6 nM.

N-hydroxymethyl succinimide is used as pharmaceutical intermediate.

Lapyrium chloride(NSC-33659) is used as a cosmetic ingredient, cationic emulsifier, detergent-germicide, deodorant and anti-static agent.

Macimorelin (EP-1572) acetate, a GH secretagogue, is an orally active GHSR agonist. Macimorelin acetate stimulates GH release. Macimorelin acetate can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS).

18-Hydroxycortisol is an endogenous steroid that secreted by the adrenal cortex. 18-Hydroxycortisol is a cortisol derivative and a steroidogenic intermediate. 18-Hydroxycortisol can be used for primary aldosteronism (PA) research.

INCB3619 is a selective and orally active ADAM inhibitor with IC50 of 22 nM and 14 nM for ADAM10 and ADAM17, respectively. INCB3619 has anti-tumor activity.

MMV676584 has anti-tuberculosis avtivity. MMV676584 is a novel drug candidate for eumycetoma.

(S)-ar-Curcumene ((+)-alpha-Curcumene) is a natural compound. (S)-ar-Curcumene is a constituent of the essential oil that can isolated from the rhizomes of Curcuma aromatica and is an odour component of distantly related corals.

5'-Hydroxy-staurosporine is an indolocarbazole alkaloid that can be isolated from marine Micromonospora sp. (strain L-31-CLCO-002). 5'-Hydroxy-staurosporine can be used in tumor related research.

RTA 744 (WP 744) is a Doxorubicin analogue. RTA 744 triggers apoptosis and cell killing in NB cells by activating proapoptotic mediators. RTA 744 has proapoptotic and anti-leukemia activities. RTA 744 can be used for cancer research.

Flurandrenolone Acetate is a derivative of Flurandrenolide. Flurandrenolone Acetate is a synthetic glucocorticoid steroid, can be used for the research of skin disorders such as eczema and psoriasis.